These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31564609)

  • 1. Perspective: Clinical relevance of the dichotomous classification of Alzheimer's disease biomarkers: Should there be a "gray zone"?
    McRae-McKee K; Udeh-Momoh CT; Price G; Bajaj S; de Jager CA; Scott D; Hadjichrysanthou C; McNaughton E; Bracoud L; Ahmadi-Abhari S; de Wolf F; Anderson RM; Middleton LT;
    Alzheimers Dement; 2019 Oct; 15(10):1348-1356. PubMed ID: 31564609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
    Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
    Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI.
    Lowe VJ; Peller PJ; Weigand SD; Montoya Quintero C; Tosakulwong N; Vemuri P; Senjem ML; Jordan L; Jack CR; Knopman D; Petersen RC
    Neurology; 2013 Jun; 80(23):2130-7. PubMed ID: 23645596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping CSF biomarker profiles onto NIA-AA guidelines for Alzheimer's disease.
    Alexopoulos P; Roesler J; Thierjung N; Werle L; Buck D; Yakushev I; Gleixner L; Kagerbauer S; Ortner M; Grimmer T; Kübler H; Martin J; Laskaris N; Kurz A; Perneczky R
    Eur Arch Psychiatry Clin Neurosci; 2016 Oct; 266(7):587-97. PubMed ID: 26253588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The National Institute on Aging-Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials.
    Cummings J
    Alzheimers Dement; 2019 Jan; 15(1):172-178. PubMed ID: 29936146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
    Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
    J Alzheimers Dis; 2015; 47(1):231-42. PubMed ID: 26402771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
    Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
    Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Causes and Patterns of Dementia: An Update in the Era of Redefining Alzheimer's Disease.
    James BD; Bennett DA
    Annu Rev Public Health; 2019 Apr; 40():65-84. PubMed ID: 30642228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.
    Edmonds EC; Bangen KJ; Delano-Wood L; Nation DA; Furst AJ; Salmon DP; Bondi MW;
    J Int Neuropsychol Soc; 2016 Nov; 22(10):978-990. PubMed ID: 27903335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Education on Alzheimer's Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer's Disease: A Cross-Sectional Study.
    Wada M; Noda Y; Shinagawa S; Chung JK; Sawada K; Ogyu K; Tarumi R; Tsugawa S; Miyazaki T; Yamagata B; Graff-Guerrero A; Mimura M; Nakajima S;
    J Alzheimers Dis; 2018; 63(2):861-869. PubMed ID: 29689728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2017 Apr; 13(4):e1-e85. PubMed ID: 28342697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A methodological critique of the National Institute of Aging and Alzheimer's Association Guidelines for Alzheimer's disease, dementia, and mild cognitive impairments.
    Garrett MD; Valle R
    Dementia (London); 2016 Mar; 15(2):239-54. PubMed ID: 24662500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease.
    Cohen AD; Landau SM; Snitz BE; Klunk WE; Blennow K; Zetterberg H
    Mol Cell Neurosci; 2019 Jun; 97():3-17. PubMed ID: 30537535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revisiting the framework of the National Institute on Aging-Alzheimer's Association diagnostic criteria.
    Carrillo MC; Dean RA; Nicolas F; Miller DS; Berman R; Khachaturian Z; Bain LJ; Schindler R; Knopman D;
    Alzheimers Dement; 2013 Sep; 9(5):594-601. PubMed ID: 24007744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials.
    Iwatsubo T; Iwata A; Suzuki K; Ihara R; Arai H; Ishii K; Senda M; Ito K; Ikeuchi T; Kuwano R; Matsuda H; ; Sun CK; Beckett LA; Petersen RC; Weiner MW; Aisen PS; Donohue MC;
    Alzheimers Dement; 2018 Aug; 14(8):1077-1087. PubMed ID: 29753531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
    Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
    Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NIA-AA Alzheimer's Disease Framework: Clinical Characterization of Stages.
    Petersen RC; Wiste HJ; Weigand SD; Fields JA; Geda YE; Graff-Radford J; Knopman DS; Kremers WK; Lowe V; Machulda MM; Mielke MM; Stricker NH; Therneau TM; Vemuri P; Jack CR
    Ann Neurol; 2021 Jun; 89(6):1145-1156. PubMed ID: 33772866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Supportive CSF biomarker evidence to enhance the National Institute on Aging-Alzheimer's Association criteria for diagnosis of Alzheimer's type dementia--a study from Southern India.
    Huded CB; Bharath S; Chandra SR; Sivakumar PT; Varghese M; Subramanian S
    Asian J Psychiatr; 2015 Feb; 13():44-7. PubMed ID: 25468261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.